Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (2)

Search Parameters:
Authors = Rėda Matuzevičienė

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
11 pages, 1227 KiB  
Article
Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment
by Mantas Radzevičius, Vaidas Dirsė, Indrė Klimienė, Rėda Matuzevičienė, Zita Aušrelė Kučinskienė and Valdas Pečeliūnas
Diagnostics 2022, 12(9), 2049; https://doi.org/10.3390/diagnostics12092049 - 24 Aug 2022
Cited by 3 | Viewed by 2364
Abstract
(1) Background: At diagnosis, multiplemyeloma risk estimation includes disease burden, end-organ damage, and biomarkers, with increasing emphasis on genetic abnormalities. Multicolor flow cytometry (MFC) is not always considered in risk estimation. We demonstrate associations found between genetic abnormalities and antigen expression of plasma [...] Read more.
(1) Background: At diagnosis, multiplemyeloma risk estimation includes disease burden, end-organ damage, and biomarkers, with increasing emphasis on genetic abnormalities. Multicolor flow cytometry (MFC) is not always considered in risk estimation. We demonstrate associations found between genetic abnormalities and antigen expression of plasma cells measured by MFC. (2) Methods: Single nucleotide polymorphism microarray (SNP-A) karyotyping as well as MFC using standardized next-generation flow (NGF) panels and instrument settings were performed from bone marrow aspirates at the time of diagnosis. (3) Results: We uncovered specific immunophenotype features related to different genetic risk factors. Specifically, we found higher malignant/normal plasma cell ratio and lower expression of CD27, CD38, CD45, CD56, CD117 and CD138 in higher-risk genetic groups or risk categories. Full article
(This article belongs to the Special Issue Innovations in Laboratory Hematology and Flow Cytometry)
Show Figures

Figure 1

9 pages, 868 KiB  
Article
Cure rates of childhood acute lymphoblastic leukemia in Lithuania and the benefit of joining international treatment protocol
by Goda Vaitkevičienė, Rėda Matuzevičienė, Mindaugas Stoškus, Tadas Žvirblis, Lina Ragelienė and Kjeld Schmiegelow
Medicina 2014, 50(1), 28-36; https://doi.org/10.1016/j.medici.2014.05.005 - 6 Jun 2014
Cited by 7 | Viewed by 1058
Abstract
Background: Childhood acute lymphoblastic leukemia (ALL) represents the largest group of pediatric malignancies with long-term survival rates of more than 80% achieved in developed countries. Epidemiological data and survival rates of childhood ALL in Lithuania were lacking. Therefore, the aim of this study [...] Read more.
Background: Childhood acute lymphoblastic leukemia (ALL) represents the largest group of pediatric malignancies with long-term survival rates of more than 80% achieved in developed countries. Epidemiological data and survival rates of childhood ALL in Lithuania were lacking. Therefore, the aim of this study was to analyze the population-based long-term treatment results of childhood ALL in Lithuania during 1992–2012.
Materials and methods: Data of all 459 children with T-lineage and B-cell precursor ALL treated in Lithuania from 1992 to 2012 were collected and analyzed. Results were compared among four time-periods: 1992–1996 (N = 132), 1997–2002 (N = 136), 2003–2008 (N = 109) and 2009–2012 (N = 82).
Results: The incidence of childhood ALL in Lithuania was 3.2–3.6 cases per 100 000 children per year during the study period. Five-year probability of event-free survival increased from 50% 4% in 1992–1996 to 71% ± 4% in 2003–2008 (P < 0.001). Five-year cumulative incidence of relapses reduced from 27% ± 4.5% in 1992–1996 to 14% ± 3.6% in 2003–2008 (P = 0.042). After introduction of high-dose methotrexate of 5 g/m2, cumulative incidence of CNSinvolving relapses reduced from 17% ± 3.9% in 1992–1996 to 1% ± 1.0% in 2003–2008 (P < 0.001). Trend for further improvement in survival was seen in 2009–2012 when Lithuania joined international the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL-2008 treatment protocol.
Conclusions: Cure rates of childhood ALL in Lithuania are improving steadily and are now approaching those reported by the largest international study groups. The reasons for such a positive effect are both better financial support for treatment of children with cancer in Lithuania and international collaboration with joining international treatment protocol for childhood ALL. Full article
Back to TopTop